Last reviewed · How we verify
NCT05049408
Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
trial testing MMP-1 Enzyme Linked Immunosorbent assay (ELISA) in Oral Squamous Cell Carcinoma in 1,160 participants. Completed in 7 December 2016.
7 December 2016
Quick facts
| Lead sponsor | S&T Biomed Co., Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,160 |
| Start date | 17 February 2011 |
| Primary completion | 7 December 2016 |
| Estimated completion | 7 December 2016 |
| Sites | 2 locations across Taiwan |
Drugs / interventions tested
- MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
Conditions studied
- Oral Squamous Cell Carcinoma — all drugs for Oral Squamous Cell Carcinoma →
Sponsor
S&T Biomed Co., Ltd.
Who can join
20 and older, any sex, with Oral Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is designed to measure salivary matrix metalloproteinase-1 (MMP-1) using the enzyme-linked immunosorbent assay (ELISA) we developed previously in patients with oral potentially malignant disorders (OPMD), oral squamous cell carcinoma (OSCC), and healthy participants. The purpose of this study is to evaluate the potential of the newly developed salivary MMP-1 ELISA as an adjunctive tool to aid in diagnosis of OSCC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05049408
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oral Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07063212 — A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) · Phase 2 · recruiting
- NCT06627270 — Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer · Phase 2 · recruiting
- NCT06055868 — People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity · recruiting
- NCT06321003 — SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography · recruiting
- NCT06258811 — Neoadjuvant Immunochemotherapy for LAOSCC · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05049408 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by S&T Biomed Co., Ltd.
- Last refreshed: 28 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05049408.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing